MEDVi Review

What MEDVi charges

MEDVi advertises $179. That buys the first month. The standing rate is $249/month, and that is the one worth doing arithmetic on, because the introductory figure applies once.

• Compounded semaglutide — $179 first month, then $299/month
• Compounded semaglutide — $249/month
• Brand-name semaglutide — $99/month
• Brand-name tirzepatide — $99/month

The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Discounting the first month does not change the twelve-month total by much.

Breeze Meds dispenses semaglutide and tirzepatide from $199/month, which makes it the honest comparison to run before committing here.

What MEDVi dispenses

MEDVi prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. The choice is between an FDA-approved pen and a compounded preparation that costs less. Compounding is lawful and often appropriate, but a compounded product is not an approved one, and the price gap is largely that difference.

A needle-free oral option is genuinely uncommon and is the reason some readers will look at MEDVi at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a demonstrated equal to the shot.

What we could verify

On the record: it treats patients in all 50 states, it names the pharmacy that fills its prescriptions, and coaching is included rather than sold on top. FDA has sent this operator a warning letter, and we flag it at the top of the page. A letter is a disclosure, not a disqualification: read what it actually says before deciding what it means for you. Because the medication is compounded, the named pharmacy is the detail that matters most here — it is the license you can actually look up. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.

Who should look elsewhere

• You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
• You would be choosing on the advertised figure. The introductory month is real, but it is not what you will be paying in month three.
• You need to bill insurance. Like most of this market, this is cash-pay.
• A regulatory record matters to you more than price does — read the warning letter flagged above before deciding.

It fits if

• you want a cheap way to find out whether the medication suits you before committing
• injections are the thing keeping you from starting
• you want coaching bundled rather than metered
• you need access regardless of where you live

Our read

MEDVi is a cheap way to start and an ordinary way to continue. Use the $179 month for what it is good for — establishing whether the medication works for you — and re-run the numbers against $249/month before you let it renew twice. Direct Meds is the nearest comparison we track, and worth reading alongside this. Whatever you decide, read the warning letter flagged at the top of this page first, and raise it with the clinician you would be prescribing through.